VENTYX BIOSCIENCES INC (VTYX)
US92332V1070 - Common Stock
VENTYX BIOSCIENCES INC
NASDAQ:VTYX (4/18/2024, 7:27:24 PM)
After market: 4.35 0 (0%)4.35
-0.03 (-0.68%)
Company Profile
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 99 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX958 (TYK2 Inhibitor), VTX002 (S1P1R Modulator), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor.
Company Info
VENTYX BIOSCIENCES INC
12790 El Camino Real, Suite 200
San Diego CALIFORNIA
P: 18589452393
Employees: 99
Website: https://ventyxbio.com/
VTYX News
7 hours ago - Kirby McInerney LLPVTYX INVESTOR ALERT: Kirby McInerney LLP Alerts Ventyx Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
12 hours ago - TheNewswire.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYXWHY: NEW YORK, NY - (NewMediaWire) - April 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.
12 hours ago - NewMediaWireROSEN, LEADING TRIAL ATTORNEYS, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYXSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
a day ago - Market News VideoRSI Alert: Ventyx Biosciences (VTYX) Now Oversold
a day ago - Robbins LLPVTYX Stockholders are Encouraged to Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Ventyx Biosciences, Inc. Class Action
2 days ago - Faruqi & Faruqi LLPSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of VentyxVTYX Twits
Here you can normally see the latest stock twits on VTYX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
